| 000 | 01778 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516172440.0 | ||
| 264 | 0 | _c20141208 | |
| 008 | 201412s 0 0 chi d | ||
| 022 | _a1007-3418 | ||
| 024 | 7 |
_a10.3760/cma.j.issn.1007-3418.2013.07.007 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChen, Xue-fu | |
| 245 | 0 | 0 |
_a[HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment]. _h[electronic resource] |
| 260 |
_bZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology _cJul 2013 |
||
| 300 |
_a502-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGuanine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aHepatitis B e Antigens _xblood |
| 650 | 0 | 4 |
_aHepatitis B, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xadministration & dosage |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aChen, Xiao-ping | |
| 700 | 1 | _aMa, Xiao-jun | |
| 700 | 1 | _aChen, Wen-li | |
| 700 | 1 | _aLuo, Xiao-dan | |
| 700 | 1 | _aLiao, Jin-yao | |
| 773 | 0 |
_tZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology _gvol. 21 _gno. 7 _gp. 502-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3760/cma.j.issn.1007-3418.2013.07.007 _zAvailable from publisher's website |
| 999 |
_c23124799 _d23124799 |
||